13.45 USD
▼-0.54-3.86%
盘后 14.66 0.00%
2026-11-19
市值
$2.39B
市盈率
132.84
EPS
0.10
股息率
—
52 周区间
9.77 – 16.33
成交量
37.53K
Beta
0.50
目标价
21.14
52W 低 9.7752W 高 16.33
价格走势

公司简介

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet...

关联新闻